Adjuvant Systemic Therapies for Patients with Renal Cell Carcinoma: Choosing Treatment Based on Patient-level Characteristics.
Publication
, Journal Article
Msaouel, P; Grivas, P; Zhang, T
Published in: Eur Urol Oncol
June 2022
Motivated by recent presentation of the KEYNOTE-564 interim results for adjuvant pembrolizumab in clear-cell renal cell carcinoma, we discuss concepts that can guide patient-specific decision-making in selecting individuals for whom adjuvant therapies should be offered.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Eur Urol Oncol
DOI
EISSN
2588-9311
Publication Date
June 2022
Volume
5
Issue
3
Start / End Page
265 / 267
Location
Netherlands
Related Subject Headings
- Kidney Neoplasms
- Immunotherapy
- Humans
- Combined Modality Therapy
- Chemotherapy, Adjuvant
- Carcinoma, Renal Cell
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Msaouel, P., Grivas, P., & Zhang, T. (2022). Adjuvant Systemic Therapies for Patients with Renal Cell Carcinoma: Choosing Treatment Based on Patient-level Characteristics. Eur Urol Oncol, 5(3), 265–267. https://doi.org/10.1016/j.euo.2021.09.003
Msaouel, Pavlos, Petros Grivas, and Tian Zhang. “Adjuvant Systemic Therapies for Patients with Renal Cell Carcinoma: Choosing Treatment Based on Patient-level Characteristics.” Eur Urol Oncol 5, no. 3 (June 2022): 265–67. https://doi.org/10.1016/j.euo.2021.09.003.
Msaouel P, Grivas P, Zhang T. Adjuvant Systemic Therapies for Patients with Renal Cell Carcinoma: Choosing Treatment Based on Patient-level Characteristics. Eur Urol Oncol. 2022 Jun;5(3):265–7.
Msaouel, Pavlos, et al. “Adjuvant Systemic Therapies for Patients with Renal Cell Carcinoma: Choosing Treatment Based on Patient-level Characteristics.” Eur Urol Oncol, vol. 5, no. 3, June 2022, pp. 265–67. Pubmed, doi:10.1016/j.euo.2021.09.003.
Msaouel P, Grivas P, Zhang T. Adjuvant Systemic Therapies for Patients with Renal Cell Carcinoma: Choosing Treatment Based on Patient-level Characteristics. Eur Urol Oncol. 2022 Jun;5(3):265–267.
Published In
Eur Urol Oncol
DOI
EISSN
2588-9311
Publication Date
June 2022
Volume
5
Issue
3
Start / End Page
265 / 267
Location
Netherlands
Related Subject Headings
- Kidney Neoplasms
- Immunotherapy
- Humans
- Combined Modality Therapy
- Chemotherapy, Adjuvant
- Carcinoma, Renal Cell
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences